CHMP Backs Lyrokaul Monthly PCSK9 Shot
CHMP Lyrokaul lerodalcibep cholesterol recommendation adds a once-monthly self-injectable PCSK9 option to Europe's lipid pipeline. EMA said on 24 July 2026 that the committee backed Lyrokaul for primary hypercholesterolaemia or mixed dyslipidaemia alongside two oral obicetrapib medicines.
Contents9 sections
Key Takeaways
- CHMP recommended Lyrokaul (lerodalcibep) as a monthly self-injection for high cholesterol / mixed dyslipidaemia.
- Use is in addition to diet; alone or with other lipid-lowering therapies.
- Same July package included oral Ubeslo and Evlarco (obicetrapib ± ezetimibe).
- Lerodalcibep already holds U.S. FDA approval as LEROCHOL (December 2025).
Lyrokaul CHMP opinion at a glance
| Field | Detail |
|---|---|
| Product | Lyrokaul (lerodalcibep) |
| Class | PCSK9 inhibitor (Adnectin–albumin fusion) |
| Dosing form cited | Monthly self-administered injection |
| EU status | CHMP positive opinion (July 2026) |
| Indication sought | Primary hypercholesterolaemia or mixed dyslipidaemia |
| U.S. brand / status | LEROCHOL — FDA approved 12 December 2025 |
| Next step | European Commission decision |
What did EMA announce?
EMA's July CHMP highlights grouped three lipid medicines: monthly injectable Lyrokaul and oral daily Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe). All three are positioned as add-ons to diet for adults with elevated cholesterol or mixed dyslipidaemia, alone or with other lipid therapies.
Source: EMA CHMP meeting highlights 20–23 July 2026.
How does the U.S. approval frame the molecule?
Everest Medicines reported FDA approval of LEROCHOL (lerodalcibep-liga) on 12 December 2025 for LDL-C lowering in adults with hypercholesterolemia including HeFH, describing a once-monthly 300 mg subcutaneous regimen with extended room-temperature stability. That U.S. label context helps European readers understand the modality while they wait for EU Product Information.
Source: Everest Medicines' PR Newswire notice of FDA LEROCHOL approval. Broader LDL-C trial activity is indexed on ClinicalTrials.gov.
Why does a monthly PCSK9 shot matter in Europe?
- Many high-risk patients still miss guideline LDL-C goals on statins ± ezetimibe
- Monoclonal PCSK9 antibodies already validated the target; dosing convenience and storage differ by product
- July's trio (injectable PCSK9 + oral CETP inhibitor ± ezetimibe) expands non-statin choice sets for HTA bodies
CHMP opinions on Ubeslo/Evlarco are covered separately on NovaPharma; Lyrokaul is the injectable counterpart in the same plenary package and should not be confused with those oral CETP products. For lipid clinics, a self-administered monthly schedule could matter for patients who struggle with biweekly or monthly monoclonal injections, provided EU Product Information confirms home-use instructions and cold-chain flexibility similar to the U.S. presentation.
Payers will still compare absolute LDL-C lowering, acquisition cost, and whether cardiovascular outcome evidence is required beyond surrogate lipid endpoints. Until the Commission decision and national HTA reviews land, Lyrokaul remains a recommended — not authorised — medicine in the EU.
What remains uncertain?
EU SmPC dosing, immunogenicity language for the Adnectin construct, and NRDL-style national pricing will determine uptake versus established PCSK9 mAbs. Cardiovascular outcome data, if required by payers beyond LDL-C lowering, may still influence reimbursement even after EC authorisation.
Related NovaPharma coverage
- CHMP Backs Obicetrapib Ubeslo and Evlarco
- CHMP July 2026: 12 New Medicines Recommended
- EC Approves Wegovy Pill, First Oral GLP-1 in EU
Frequently Asked Questions
What did CHMP recommend for Lyrokaul?
EMA said CHMP recommended marketing authorisation for Lyrokaul (lerodalcibep), a monthly self-administered injection, for adults with primary hypercholesterolaemia or mixed dyslipidaemia, in addition to diet, alone or with other lipid-lowering therapies. The opinion came alongside oral obicetrapib products Ubeslo and Evlarco in the same July 2026 lipid package.
Is lerodalcibep already approved in the United States?
Yes. Everest Medicines previously reported that the U.S. FDA approved LEROCHOL (lerodalcibep-liga) on 12 December 2025 as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
What happens next in Europe?
The CHMP opinion goes to the European Commission for a centralised marketing-authorisation decision. Pricing and reimbursement remain national after any EC approval.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Lyrokaul.
Unlock full calendar →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
